Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;21(12):1672-1679.
doi: 10.1038/mp.2016.180. Epub 2016 Oct 4.

In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study

S E Holmes  1 , R Hinz  2 , R J Drake  3 , C J Gregory  1 , S Conen  1 , J C Matthews  2 , J M Anton-Rodriguez  2 , A Gerhard  1 , P S Talbot  1
Affiliations

In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study

S E Holmes et al. Mol Psychiatry. 2016 Dec.

Abstract

Positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO) has been used to investigate whether microglial activation, an indication of neuroinflammation, is evident in the brain of adults with schizophrenia. Interpretation of these studies is confounded by potential modulatory effects of antipsychotic medication on microglial activity. In the first such study in antipsychotic-free schizophrenia, we have used [11C](R)-PK11195 PET to compare TSPO availability in a predominantly antipsychotic-naive group of moderate-to-severely symptomatic unmedicated patients (n=8), similarly symptomatic medicated patients with schizophrenia taking risperidone or paliperidone by regular intramuscular injection (n=8), and healthy comparison subjects (n=16). We found no evidence for increased TSPO availability in antipsychotic-free patients compared with healthy controls (mean difference 4%, P=0.981). However, TSPO availability was significantly elevated in medicated patients (mean increase 88%, P=0.032) across prefrontal (dorsolateral, ventrolateral, orbital), anterior cingulate and parietal cortical regions. In the patients, TSPO availability was also strongly correlated with negative symptoms measured using the Positive and Negative Syndrome Scale across all the brain regions investigated (r=0.651-0.741). We conclude that the pathophysiology of schizophrenia is not associated with microglial activation in the 2-6 year period following diagnosis. The elevation in the medicated patients may be a direct effect of the antipsychotic, although this study cannot exclude treatment resistance and/or longer illness duration as potential explanations. It also remains to be determined whether it is present only in a subset of patients, represents a pro- or anti-inflammatory state, its association with primary negative symptoms, and whether there are significant differences between antipsychotics.

PubMed Disclaimer

Comment in

  • Microglia and schizophrenia: where next?
    Notter T, Meyer U. Notter T, et al. Mol Psychiatry. 2017 Jun;22(6):788-789. doi: 10.1038/mp.2017.67. Epub 2017 Mar 28. Mol Psychiatry. 2017. PMID: 28348384 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nature. 2009 Aug 6;460(7256):753-7 - PubMed
    1. Neuroimage. 2008 Apr 1;40(2):672-84 - PubMed
    1. J Cereb Blood Flow Metab. 2007 Dec;27(12 ):1965-74 - PubMed
    1. Neurosci Biobehav Rev. 2013 Sep;37(8):1680-91 - PubMed
    1. Schizophr Bull. 2015 Jan;41(1):85-93 - PubMed

Publication types

-